By Fineline Cube 
Shenzhen-based Immvira Bioscience Inc. has filed for an initial public offering (IPO) with the Hong Kong Stock Exchange, with Citigroup and CICC acting as joint sponsors. Details regarding the unit price and other key financials remain undisclosed at this stage.
Company Overview
Immvira is a clinical-stage biotech company specializing in the development of novel oncolytic immunotherapies and engineered exosome therapies using proprietary bioengineering technologies. Its product pipeline includes two clinical-stage oncolytic immunotherapy candidates, two preclinical engineered exosome candidates, and three commercially ready engineered exosome products, one of which is already commercialized via INCI registration.
Lead Product Candidates
Immvira’s core product, MVR-T3011, is engineered on an optimized HSV-1 backbone. It can express anti-PD-(L)1 antibody and IL-12, offering high replicative capacity and versatile administration routes including intratumoral, intravesical, and intravenous injection. This positions it as a promising treatment for multiple solid tumors such as bladder cancer and head and neck squamous cell carcinoma (HNSCC).
Another key candidate, MVR-C5252, also leverages the HSV-1 platform and is designed to combat malignant glioma. The drug candidate is engineered to delete neurotoxic-related genes while retaining immune-activating components to enhance the safety of intracranial administration.
Financial Snapshot
In the first quarter of 2025, Immvira reported revenue of RMB 1.3 million (USD 188,000) and a net loss of RMB 204 million (USD 28 million).-Fineline Info & Tech